Caregen Co.Ltd (214370) - Total Assets
Based on the latest financial reports, Caregen Co.Ltd (214370) holds total assets worth ₩233.98 Billion KRW (≈ $158.57 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 214370 total equity for net asset value and shareholders' equity analysis.
Caregen Co.Ltd - Total Assets Trend (2015–2024)
This chart illustrates how Caregen Co.Ltd's total assets have evolved over time, based on quarterly financial data.
Caregen Co.Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
Caregen Co.Ltd's total assets of ₩233.98 Billion consist of 40.1% current assets and 60.0% non-current assets.
| Asset Category | Amount (KRW) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | ₩5.06 Billion | 2.1% |
| Accounts Receivable | ₩32.97 Billion | 13.7% |
| Inventory | ₩18.11 Billion | 7.5% |
| Property, Plant & Equipment | ₩125.59 Billion | 52.2% |
| Intangible Assets | ₩4.95 Billion | 2.1% |
| Goodwill | ₩0.00 | 0.0% |
Asset Composition Trend (2015–2024)
This chart illustrates how Caregen Co.Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 214370 market cap overview.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Caregen Co.Ltd's current assets represent 40.1% of total assets in 2024, a decrease from 85.2% in 2015.
- Cash Position: Cash and equivalents constituted 2.1% of total assets in 2024, down from 45.6% in 2015.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, an increase from 0.0% in 2015.
- Asset Diversification: The largest asset category is property, plant & equipment at 52.2% of total assets.
Caregen Co.Ltd Competitors by Total Assets
Key competitors of Caregen Co.Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
KPX Lifescience.Co.Ltd
KQ:114450
|
Korea | ₩50.34 Billion |
|
GeneBioTech Co. Ltd
KQ:086060
|
Korea | ₩75.43 Billion |
|
Sam Chun Dang Pharm. Co. Ltd
KQ:000250
|
Korea | ₩529.96 Billion |
|
ST Pharm Co.Ltd
KQ:237690
|
Korea | ₩782.57 Billion |
|
Oscotec Inc
KQ:039200
|
Korea | ₩154.14 Billion |
|
NatureCell Co.Ltd
KQ:007390
|
Korea | ₩71.32 Billion |
|
Mezzion Pharma Co.Ltd
KQ:140410
|
Korea | ₩87.88 Billion |
|
Huons Global Co. Ltd
KQ:084110
|
Korea | ₩1.47 Trillion |
Caregen Co.Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 13.01 | 9.95 | 11.55 |
| Quick Ratio | 10.29 | 8.14 | 11.01 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | ₩82.83 Billion | ₩87.12 Billion | ₩128.49 Billion |
Caregen Co.Ltd - Advanced Valuation Insights
This section examines the relationship between Caregen Co.Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 14.38 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | -2.7% |
| Total Assets | ₩240.70 Billion |
| Market Capitalization | $768.08 Million USD |
Valuation Analysis
Below Book Valuation: The market values Caregen Co.Ltd's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Caregen Co.Ltd's assets decreased by 2.7% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Caregen Co.Ltd (2015–2024)
The table below shows the annual total assets of Caregen Co.Ltd from 2015 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | ₩240.70 Billion ≈ $163.12 Million |
-2.66% |
| 2023-12-31 | ₩247.28 Billion ≈ $167.58 Million |
+5.64% |
| 2022-12-31 | ₩234.07 Billion ≈ $158.63 Million |
+3.22% |
| 2021-12-31 | ₩226.76 Billion ≈ $153.67 Million |
+4.71% |
| 2020-12-31 | ₩216.56 Billion ≈ $146.76 Million |
-6.60% |
| 2019-12-31 | ₩231.85 Billion ≈ $157.12 Million |
+5.90% |
| 2018-12-31 | ₩218.94 Billion ≈ $148.37 Million |
-11.37% |
| 2017-12-31 | ₩247.02 Billion ≈ $167.40 Million |
-0.85% |
| 2016-12-31 | ₩249.13 Billion ≈ $168.83 Million |
-2.88% |
| 2015-12-31 | ₩256.52 Billion ≈ $173.84 Million |
-- |
About Caregen Co.Ltd
Caregen Co., Ltd. engages in the research, development, and commercialization of biomimetic peptides and growth factors worldwide. The company offers cosmeceutical products and food supplements under the Dermaheal, Renokin, Deglusterol, PURILUX, Pelo Baum, Pim-Pim-Paul, Neovert, and PTx brands. It also provides medical devices under the REVOFIL, DR.CYJ, PROSTROLANE, PROSTROLANE B-Series, and CG S… Read more